No Data
No Data
Black Diamond Theraptcs Is Maintained at Buy by HC Wainwright & Co.
Black Diamond Theraptcs Is Maintained at Buy by HC Wainwright & Co.
Black Diamond Therapeutic Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 100% HC Wainwright & Co. $12 → $11 Maintains Buy 04/08/2024 190.91% Wedbush $10 → $16 Maintains
Buy Rating Affirmed for Black Diamond Therapeutics Amid Strong Financials and Promising Clinical Trials
Express News | Black Diamond Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $11 From $12
Express News | Black Diamond Therapeutics Expects Cash & Equivalents Of $115.2M As Of March-End To Be Sufficient To Fund Operations Into Q3 Of 2025
Express News | Black Diamond Therapeutics Inc: Cash, Cash Equivalents, and Investments of $115.2 Mln as of March 31, 2024